Literature DB >> 7797041

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

H Mertz1, B Naliboff, J Munakata, N Niazi, E A Mayer.   

Abstract

BACKGROUND & AIMS: Lowered visceral perception thresholds have been suggested as a biological marker of irritable bowel syndrome (IBS). The current study sought to determine the prevalence of altered rectal visceral perception in patients with IBS and the correlation of altered perception thresholds with subjective symptoms.
METHODS: Anorectal manometry and rectal perception thresholds to balloon distention were determined in 100 patients with IBS and 15 control subjects. Gastrointestinal and psychological symptoms were assessed by questionnaire. Perception thresholds and symptoms were reassessed after 3 months in 15 patients with IBS.
RESULTS: Ninety-four percent of patients showed altered rectal perception in the form of lowered thresholds for aversive sensations (discomfort), increased intensity of sensations, or altered viscerosomatic referral. Hypersensitivity was found only for aversive sensations in response to rapid phasic distention; stool thresholds and thresholds in response to slow ramp distention were normal. Cluster analysis by physiological parameters identified three IBS subgroups with predominant patterns of symptoms. Longitudinal evaluation indicated a correlation between changes in perception thresholds and symptom severity.
CONCLUSIONS: Because altered rectal perception is present in almost all patients with IBS and perception thresholds correlate with temporal changes in retrospective symptom severity, altered rectal perception represents a reliable biological marker of IBS.

Entities:  

Mesh:

Year:  1995        PMID: 7797041     DOI: 10.1016/0016-5085(95)90267-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  218 in total

Review 1.  Spinal and supraspinal modulation of visceral sensation.

Authors:  E A Mayer
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Colonic motor function in humans is not affected by gender.

Authors:  E E Soffer; K Kongara; J P Achkar; J Gannon
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

3.  Irritable Bowel Syndrome.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

Review 4.  Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls.

Authors:  M Camilleri
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 5.  Centrally acting agents and visceral sensitivity.

Authors:  J Fioramonti; L Bueno
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 6.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

7.  Cortical and spinal evoked potential response to electrical stimulation in human rectum.

Authors:  Brian Garvin; Lisa Lovely; Alex Tsodikov; Danielle Minecan; Shaungson Hong; John W Wiley
Journal:  World J Gastroenterol       Date:  2010-11-21       Impact factor: 5.742

8.  Chronic prenatal stress epigenetically modifies spinal cord BDNF expression to induce sex-specific visceral hypersensitivity in offspring.

Authors:  J H Winston; Q Li; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2014-03-04       Impact factor: 3.598

9.  Cerebral processing of auditory stimuli in patients with irritable bowel syndrome.

Authors:  Viola Andresen; Alexander Poellinger; Chedwa Tsrouya; Dominik Bach; Albrecht Stroh; Annette Foerschler; Petra Georgiewa; Marco Schmidtmann; Ivo R van der Voort; Peter Kobelt; Claus Zimmer; Bertram Wiedenmann; Burghard F Klapp; Hubert Monnikes
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

10.  Colorectal visceral perception in diverticular disease.

Authors:  C H M Clemens; M Samsom; J Roelofs; G P van Berge Henegouwen; A J P M Smout
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.